Want to join the conversation?
$BIIB expects R&D expense for 2016 to be approx. 19% to 20% of sales, including about $100MM earmarked for business development activity. The Company plans to continue to invest in a number of R&D programs across late-stage pipeline during 2016, including aducanumab for Alzheimer's disease and nusinersen for spinal muscular atrophy.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?